No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
300485 Beijing Science Sun Pharmaceutical
- 6.80
- +0.06+0.89%
Market Closed Jan 27 15:00 CST
3.28BMarket Cap-17.09P/E (TTM)
6.98High6.76Low38.64KlotVolume6.80Open6.74Pre Close26.55MTurnover1.41%Turnover Ratio31.78P/E (Static)481.67MShares9.4552wk High0.98P/B1.86BFloat Cap5.7352wk Low8.09Limit Up273.82MShs Float43.34Historical High5.39Limit Down3.26%Amplitude5.73Historical Low0.02Dividend TTM6.87Avg Price17.33KlotAsk0.32%Div YieldTTM100Lot Size20.85KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Beijing Science Sun Pharmaceutical's Unit Gets Renewed Drug Production License
Beijing Science Sun Pharmaceutical (300485.SZ): Anticipated loss of 59.1728 million yuan to -88.7592 million yuan for the fiscal year 2024.
Gelonghui, January 24丨Beijing Science Sun Pharmaceutical (300485.SZ) announced its performance forecast for 2024. The total profit for 2024 is expected to incur a loss of 0.105 billion yuan to 85.9852 million yuan, and the Net income attributable to shareholders of the listed company is expected to be a loss of 88.7592 million yuan to 59.1728 million yuan. The Net income after deducting non-recurring gains and losses is expected to be a profit of 11.5631 million yuan to 17.3447 million yuan, with revenue expected to be between 0.396 billion yuan and 0.438 billion yuan. During the reporting period, the company recognized the fair value changes of financial assets and the investment income from joint ventures in accordance with the new financial instrument standards.
Express News | Beijing Science Sun Pharmaceutical: It is expected that the net income in 2024 will be a loss of 88.7592 million yuan—59.1728 million yuan.
Saisheng Pharmaceutical: 2024 Annual Performance Forecast
Saisheng Pharmaceutical (300485.SZ): Subsidiary dapagliflozin API marketing application accepted
On December 23, the company Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary, Beijing Sai'er Biopharmaceutical Co., Ltd. (hereinafter referred to as "Sai'er Biopharmaceutical"), has recently received the "Acceptance Notice" for the marketing application of Dapagliflozin Active Pharmaceutical Ingredient issued by the National Medical Products Administration. Dapagliflozin is a new type of oral hypoglycemic agent, originally developed by Bristol-Myers Squibb, which later licensed the intellectual property and Global production and sales rights to AstraZeneca. In 2012, Dapagliflozin was approved by the European EMA for the treatment of type 2 diabetes, becoming the first drug in the SGLT-2 class approved globally; in 2014, it was approved in the USA.
Science Sun Pharmaceutical's Unit Completes License Amendment